Table IV.
Expt. | Target Cell | HLA-DR4/DR7 Expression | Cell Description | BR-B8 | B104 |
---|---|---|---|---|---|
1 | Media | DR4−DR7− | None | 11 | 0 |
Donor 2 DC-888melb | DC++-mel−− | Fused adherentc | 1,475d | 725 | |
Donor 2 DC-888melb | DC++-mel−− | Fused nonadherent | 399 | 38 | |
Donor 2 DC-888melb | DC++-mel−− | Physical mixture | 0 | 7 | |
Donor 4 DC-888melb | DC++-mel−− | Fused adherente | 1,475 | 255 | |
Donor 4 DC-888melb | DC++-mel−− | Fused nonadherent | 243 | 29 | |
888melb | DR4−DR7− | Fused adherent | 0 | 0 | |
2f | Media | DR4−DR7− | None | 0 | 1 |
Donor 2 DC-888melg | DC++-mel−− | Fused adherent | 2,460 | 68 | |
Donor 5 DC-888melh | DC−−-mel−− | Fused adherent | 8 | 25 | |
3 | Media | DR4−DR7− | None | 0 | 10 |
1088 EBV-B + Flu HA:306–324 | DR4+DR7− | Nonfused | 4 | ||
1088 EBV-B + gp100:44–59 | DR4+DR7− | Nonfused | 1,664 | ||
1978 EBV-B + IgK:188–201 | DR4−DR7+ | Nonfused | 19 | ||
1978 EBV-B + gp100:170–190 | DR4−DR7+ | Nonfused | 7,541 | ||
888mel | DR4−DR7− | Nonfused | 0 | 0 | |
F002Rmel CIITA-GFP | DR4−DR7+ | Nonfused | 0 | 8 | |
F002Rmel CIITA-gp100 | DR4−DR7+ | Nonfused | 10 | >20,000 | |
624mel CIITA | DR4+DR7+ | Nonfused | 1,946 | 9,673 | |
1088mel CIITA | DR4+DR7− | Nonfused | 3,519 | 25 | |
Donor 2 DC-888melb | DC++-mel−− | Fused adherentc | 5,338 | 883 | |
Donor 2 DC-888melb | DC++-mel−− | Fused nonadherent | 937 | 66 | |
Donor 2 DC-888melb | DC++-mel−− | Physical mixture | 31 | 29 | |
888melb | DR4−DR7− | Fused adherent | 0 | 0 |
IFN-γ secretion (picograms per milliliter) in 20 h coculture supernatants of target cells with T lymphocytes. The data in each of the three panels were generated in separate experiments.
For these fused cell populations, 1 × 105 T cells were coincubated with 3.75 × 104 target cells.
In the adherent fraction of DC-888mel fusion cells from donor 2 in this experiment, 48% of cells were positive for both CFSE and HLA-DR by FACS.
Underlined values indicate that IFN-γ secretion in response to peptide-loaded EBV-B cells, melanoma cell lines, or hybrid cell populations was 50 pg/ml and at least twice background with relevant control target cells (including a physical mixture of 888 melanoma cells and DCs).
In the adherent fraction of DC-888mel fusion cells from donor 4 in this experiment, 29% of cells were positive for both CFSE and HLA-DR by FACS.
In the second experiment, 1 × 105 T cells were coincubated with 1.5 × 104 target cells.
In the adherent fraction of DC-888mel fusion cells from donor 2 in this experiment, 19% of cells were positive for both CFSE and HLA-DR by FACS.
In the adherent fraction of DC-888mel fusion cells from donor 5 in this experiment, 25% of cells were positive for both CFSE and HLA-DR by FACS.